Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approves Topical Pan-JAK Inhibitor for Chronic Hand Eczema in Adults The U.S. Food and Drug Administration (FDA) has approved a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe chronic hand eczema in ad

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition marked by painful nodules, abscesses, and scarring, most commonly in intertriginous areas such as the axillae and groin. The disease significantly impairs quality of life due to its physical, psychological, and social burden. While TNF-α inhibitors like adalimumab

Introduction: Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory skin condition that affects apocrine gland–bearing areas such as the axillae and groin. Characterized by painful nodules, abscesses, and scarring sinus tracts, HS significantly impairs quality of life. While TNF-α inhibitors like adalimumab offer clin

Alopecia Areata (AA) is known to have an unpredictable disease course, and can result in chronic and extensive hair loss, often progressing to more severe types of alopecia (1). Ritlecitinib has demonstrated sustained clinical efficacy with long-term treatment use, even in patients with extensive baseline hair loss (2). The pivotal ALLEGRO phase 2b

Vitiligo is a chronic autoimmune disease involving progressive loss of melanocytes and can impose a significant psychological burden on affected patients (1). The interferon-gamma (IFN-ɣ) driven CD8+ T cell activation via the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway plays a central role in the pathogenesis of

Introduction Zasocitinib, a next-generation oral TYK2 inhibitor, is setting a new benchmark in the treatment of moderate-to-severe psoriasis. In a recent comparative analysis, Zasocitinib demonstrated greater potency, superior selectivity, and prolonged TYK2 inhibition compared to other approved TYK2/JAK inhibitors, including deucravacitinib, baric

Introduction Oral therapies for moderate-to-severe plaque psoriasis remain limited, especially those offering biologic-level efficacy with favorable safety profiles (1). TYK2 inhibition has emerged as a targeted, selective approach that bypasses broader JAK-related adverse events. This case explores the clinical management of a middle-aged male pat

In vitiligo, the autoimmune disorder, melanocytes that are pre-exposed to environmental factors such as oxidative stress are attacked by CD8+ T cells, causing depigmentation in the skin and hair (1,2). This can be treated by triggering repigmentation through janus kinase 3 (JAK3)/ tyrosine protein kinase (TEC) inhibition, which may decrease abnorma

Introduction: Psoriasis is a chronic immune-mediated inflammatory disease affecting up to 3% of the global population (1). In patients with concomitant autoimmune diseases, treatment can be challenging due to overlapping pathogenic pathways and potential safety concerns. Multiple sclerosis (MS), a chronic demyelinating disorder of the central nervo